SCHEMBL2005577

SCHEMBL2005577

Cc1cc(C)cc(S(N)(=O)=O)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 14/20 0.56
CA1 P00915 13/20 0.56
CA9 Q16790 12/20 0.56
CA12 O43570 8/20 0.56
CA6 P23280 3/20 0.56
CA5A P35218 3/20 0.56
CA7 P43166 3/20 0.56
CA5B Q9Y2D0 3/20 0.56
CA3 P07451 2/20 0.56
ALDH1A1 P00352 2/20 0.52
KDM4E B2RXH2 1/20 0.52
APEX1 P27695 1/20 0.48
CYP2C19 P33261 1/20 0.48
CA4 P22748 3/20 0.46
CA14 Q9ULX7 3/20 0.46
TSHR P16473 2/20 0.46
CA13 Q8N1Q1 2/20 0.46
USP2 O75604 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
AGO2 Q9UKV8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12325098 0.91 ALDH1A1 (0.55) CA2CA1CA9CA12CA6
SCHEMBL4807069 0.84 CA2 (0.50) CA2CA1CA9CA12CA6
Sulfamide SCHEMBL29026073 0.82 ALDH1A1 (0.55) CA2CA1CA9CA12CA6
SCHEMBL23792366 0.80 CA2 (0.43) CA2CA1CA9CA12CA6
SCHEMBL25094400 0.80 KDM4E (0.45) CA2CA1CA9CA12CA6
Methanesulfonamide SCHEMBL4804491 0.79 CA1 (0.53) CA2CA1CA9CA12CA6
Methanesulfonamide SCHEMBL4804172 0.79 CA1 (0.53) CA2CA1CA9CA12CA6
SCHEMBL11178716 0.79 CA2 (0.44) CA2CA1CA9CA12CA6
SCHEMBL11176657 0.79 TPMT (0.59) CA2CA1CA9CA12CA6
SCHEMBL1171992 0.79 CA1 (0.52) CA2CA1CA9CA12CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119219810-A Ionic polymer and preparation method and application thereof 佛山绿动氢能科技有限公司 2024-12-31 CN claimed
CN-119219810-A Ionic polymer and preparation method and application thereof 佛山绿动氢能科技有限公司 2024-12-31 CN disclosed
CN-119219809-A Fluorine-containing polymer, preparation method thereof and ion exchange membrane 佛山绿动氢能科技有限公司 2024-12-31 CN disclosed
CN-110139854-A O- substituted isohydroxyloxime acid 约翰斯霍普金斯大学 2019-08-16 CN disclosed
CN-107922371-A Hydroxamic acid of the substitutions of the N with carbon-based leaving group as effective HNO donors and application thereof 约翰斯霍普金斯大学 2018-04-17 CN disclosed
CN-103664974-B Aryl [a] indole [2,3-g] quinolizine compounds, its preparation method, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2016-12-21 CN disclosed
CN-102388112-B Photocatalyst coating material, photocatalyst coating film, and layered coating film structure METAL-TECH LTD. (JP) 2015-08-19 CN disclosed
US-20150093692-A1 PATTERN FORMING METHOD, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION AND RESIST FILM USED THEREFOR, AND ELECTRONIC DEVICE MANUFACTURING METHOD AND ELECTRONIC DEVICE USING THE SAMEDEVICE MANUFACTURING METHOD AND ELECTRONIC DEVICE USING THE SAME FUJIFILM CORPORATION (JP) 2015-04-02 US disclosed
CN-103664974-A Aryl [a] indole [2,3-g] quinolizine compound as well as preparation method, pharmaceutical composition and application thereof SHANGHAI INST MATERIA MEDICA 2014-03-26 CN disclosed
CN-101709045-B Preparation method of thiophenol UNIV ZHEJIANG 2013-02-27 CN disclosed
US-7964633-B2 such as N,N'-[hexane-1,6-diylbis(iminocarbonyl)]bis(3-chlorobenzenesulfonamide), used as Fructose-1,6-bisphosphatase inhibitors; metabolic disorders such as diabetes HOFFMANN-LA ROCHE INC. (US) 2011-06-21 US disclosed
EP-2081889-B1 SULFONAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-12-22 EP disclosed
CN-101709045-A Preparation method of thiophenol UNIV ZHEJIANG 2010-05-19 CN disclosed
EP-2081889-A1 SULFONAMIDE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2009-07-29 EP disclosed
US-20080085928-A1 Sulfonamide derivatives HOFFMANN-LA ROCHE INC. 2008-04-10 US disclosed
WO-2008037628-A1 SULFONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-04-03 WO disclosed
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed
CN-1133703-C Latex outer wall paint and its preparation process 华南理工大学 2004-01-07 CN disclosed
CN-1308103-A Latex outer wall paint and its preparation process HUANAN SCIENCE & ENGINEERING (CN) 2001-08-15 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 CA2 743/4885CA1 838/4885CA9 495/4885
US-20080085928-A1 Sulfonamide derivatives SULT2A1, SULT1A1, SULT1E1 CA2 1137/4885CA1 2532/4885CA9 1183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.